바로가기
본문 바로가기
메인메뉴 바로가기
HOME
CONTACT US
메인메뉴
Introduction
About Lab
Contact Us
Members
Professor
Member
Alumni
Research
Research
Publications
Translational Research
Clinical Research
Journal Club
Journal Club
Board
Notice
Link
Gallery
CGRL
Cancer Genomics
Research Laboratory
Publications
Translational Research
Clinical Research
Clinical Research
Home > PUBLICATIONS > Clinical Research
No.
Journal
File
96
Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY., ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci. 2015 Jan;106(1):86-93.
95
Park HJ, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery. Anticancer Res. 2014 Nov;34(11):6685-90.
94
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW., Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 Oct;15(11):1245-53
93
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35.
92
Lee KW, Kim YJ, Lee KH, Han SW, Kim TY, Oh DY, Im SA, Kim TY, Bang YJ, Choi IS, Kim JH., Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):447-55.
91
Kwon J, Chie EK, Kim K, Kim HJ, Wu HG, Kim IH, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Ha SW., Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci. 2014 Aug;29(8):1094-101
90
Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Han W, Kim K, Chie EK, Park IA, Kim YT, Noh DY, Ha SW, Bang YJ., A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions. Cancer Res Treat. 2014 Jul;46(3):280-7.
89
Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang H5, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH, Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jun;15(7):767-74.
88
Choi Y, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ., The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. J Pain Symptom Manage. 2014 Jul;48(1):13-25.
87
Lee HJ, Kim DY, Keam B, Lee JH, Han SW, Oh DY, Yoon JH, Kim TY, Kim YJ, Lee KW, Kim JW, Jeong SH, Lee JS, Kim JH, Im SA., Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. Breast Cancer. 2014 Jul;21(4):387-93.
86
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK., Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Invest New Drugs. 2014 Jun;32(3):535-41.
85
Hong YS, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, Ahn JB, Jung KH, Im SA, Kim TY, Kim JH, Park YS, Kim TW., A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Prospective, Multicenter Trial of the Korean Cancer Study Group. Am J Clin Oncol. 2014 Feb;37(1):19-23.
84
Kim JW, Im SA, Kim MA, Cho HJ, Lee DW, Lee KH, Kim TY, Han SW, Oh DY, Lee HJ, Kim TY, Yang HK, Kim WH, Bang YJ., Ataxia-telangiectasia mutated (ATM) protein expression with microsatellite instability in gastric cancer as prognostic marker. Int J Cancer. 2014 Jan 1;134(1):72-80.
83
Lee HC, Ko H, Seol H, Noh DY, Han W, Kim TY, Im SA, Park IA., Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response. J Breast Cancer. 2013 Dec;16(4):395-403.
82
Kim JW, Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, Oh DY, Lee SH, Im SA, Kim TY, Heo DS, Bang YJ., Clinical Implications of VEGF, TGF-??1, and IL-1?? in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2013 Dec;45(4):325-33.
81
Lee JH, Chie EK, Kim K, Jeong SY, Park KJ, Park JG, Kang GH, Han SW, Oh DY, Kim TY, Bang YJ, Ha SW., The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer. BMC Cancer. 2013 Dec 5;13(1):576.
80
Finn RS, Poon RT, Yau T, Kl?mpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J., Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology. 2013 Dec;59(6):1271-7.
79
Song C, Kim K, Chie EK, Kim JH, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy. International Journal of Radiation Oncology Biology Physics. 2013 Nov 1;87(3):499-504.
78
Kim JW, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA., Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9.
77
Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, Kim TY, Ryu MH, Nam BH, Zang DY., Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Annals of Oncology. 2013 Nov;24(11):2850-4.
1
2
3
4
5
6
